Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 38, Issue 8, 1998, Pages 715-719

  Mazzu, Arthur ^a   Lettieri, John ^a   Kaiser, Lee ^a   Mullican, William ^b,c   Heller, Allen H ^a  

^a BAYER CORPORATION   (United States)

^b GFI Pharmaceutical Services Inc   (United States)

^c Medisphere   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CERIVASTATIN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENZYME INHIBITION; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0031841828     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04811.x     Document Type: Article

References (11)

1. Wenger NK: Preventive cardiology in the elderly. Curr Opin Cardiol 1997;12:195-201.
2. LaRosa JC: Dyslipidemia and coronary artery disease in the elderly. Clin Geriatr Med 1996;12:33-40.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
4. Kjekshus J, Pedersen TR: Reducing the risk of coronary events: evidence from the Scandinavian simvastatin survival study (4S). Am J Cardiol 1995;76:64C-68C.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-1009.
6. Mellis MJ, DeVault AR, Kassler-Taub K, McGovern ME, Pan HY: Pravastatin experience in elderly and non-elderly patients. Atherosclerosis 1993;101:97-110.
7. Furberg CD, Pitt B, Byington RP, Park JS, McGovern ME, PLAC I and PLAC II investigators: Reduction in coronary events during treatment with pravastatin: pravastatin limitation of atherosclerosis in the coronary arteries. Am J Cardiol 1995;76:60C-63C.
8. Stein E, Sprecher DL, Allenby KS, Tosiello R, Whalen E, Ripa SR, et al: Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: effect of 0.2 mg/day in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther 1997;2:7-16.
9. Insull W, Stein E, Whalen E, Ripa S, and the Cerivastatin Study Group: Cerivastatin: a new potent HMG-CoA reductase inhibitor: efficacy and tolerability in primary hypercholesterolemia (abstract). J Am Coll Cardiol 1997;29:46A.
10. Mazzu A, Lettieri J, Heller AH: Pharmacokinetics of cerivastatin administration with and without food in the morning and evening (abstract). Atherosclerosis 1997;139(suppl):S29.
11. Krol GJ, Beck GW, Ritter W, Lettieri JT, Ness GC, Lopez D, et al: Determination of rivastatin levels in plasma samples by HPLC and enzyme inhibition assays. In, Reid R, Wilson ID (eds.): Biofluid and Tissue Analysis for Drugs, Including Hypolipidaemics. Volume 23. Cambridge: Royal Society of Chemistry, 1994; 147-156.